Top ▲

Hemophagocytic lymphohistiocytosis

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:416
Name:Hemophagocytic lymphohistiocytosis
Associated with:1 target
1 immuno-relevant ligand
Synonyms
Hemophagocytic syndrome
Database Links
Disease Ontology: DOID:0050120
OMIM: 603552
Orphanet: ORPHA158032

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
TRPM3
Comments:  TRPM3 is a candidate gene for this disease.
References:  3-4

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
emapalumab 1
Immuno Disease Comments: Approved therapy for HLH in adult and pediatric patients (FDA 2018).
Clinical Use: Emapalumab initially received FDA orphan drug designation for the treatment of hemophagocytic lymphohistiocytosis (HLH). Link here to the FDA record for this designation.
Phase 2/3 clinical trial NCT01818492 evaluated emapalumab (NI-0501) in children with primary HLH, and a long-term follow-up study of HLH patients who were given emapalumab in an earlier clinical trial is ongoing (see NCT02069899). In November 2018, the FDA granted full approval for emapalumab's use as a treament option for adult and pediatric (newborn and older) patients with refractory, recurrent or progressive primary HLH or who are intolerant to conventional HLH therapy.

SARS-CoV-2 and COVID-19: Emapalumab has been entered in to clinical trials that aim to determine its ability to combat the exaggerated immune response that drives cytokine storm and leads to tissue damage in the lung and other organs in patients with severe COVID-19. | View clinical data
Bioactivity Comments: IFNγ binding and neutralisation by NI-0501 and results of biological function studies are provided in patent WO2006109191 [2]. | View biological activity

References

Show »

1. FDA. FDA approves emapalumab for hemophagocytic lymphohistiocytosis. Accessed on 21/11/2018. Modified on 21/11/2018. https://www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626280.htm?utm_campaign=Oncology%2011%2F20%2F2018%20emapalumab%20%28GAMIFANT&utm_medium=email&utm_source=Eloqua&elqTrackId=87dd737d161843d8a913014df8c207b1&elq=e82c83f7f52f4e0aad9b0d385665ebb3&elqaid=5965&elqat=1&elqCampaignId=4818

2. Ferlin W, Fischer N, Elson G, Leger O. (2006) Human anti-interferon gamma antibodies and methods of use thereof. Patent number: WO2006109191. Assignee: Novimmune S.A.. Priority date: 27/01/2005. Publication date: 19/10/2006.

3. Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, Huang M, Lin JH, Feder JN, Janovitz EB et al.. (2003) Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J Biol Chem, 278 (23): 20890-7. [PMID:12672827]

4. Nilius B, Owsianik G, Voets T, Peters JA. (2007) Transient receptor potential cation channels in disease. Physiol Rev, 87 (1): 165-217. [PMID:17237345]